Systemic sclerosis & Raynaud's
Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study
Authors' conclusion
Our study benchmarks the unique combined experiences of post-AHSCT management among SSc experts.
Study context
- Population
- SSc experts on post-AHSCT management in diffuse cutaneous systemic sclerosis (dcSSc)
- Participants
- 69 experts21 countries
- Outcome
- Preferred therapy in case of AHSCT failure
Methodological detailsonline questionnaire, international
- Online questionnaire
- International
Main finding
As reported in the abstract
- MMF
- N = 55, 88.7 %
- RTX
- N = 54, 87.1 %
- Nintedanib
- N = 39, 62.9 %
- Tocilizumab
- N = 36, 58.1 %
- Combination therapy with more than one of these agents considered
- N = 61, 88.4 %
Observational data: associations, not effects.
Further findings
Respondent characteristics
%
- Works at a university hospital
- 89.7
- Involved in decisions regarding AHSCT in SSc
- 71
- Most have 1 to 5 patients who underwent AHSCT under their care
Definitions of AHSCT failure and progression
- Failure to improve: increase in mRSS, new or worsening interstitial lung disease (ILD), new scleroderma renal crisis (SRC) or inflammatory arthritis
- Progression after initial response: increase in mRSS, new or worsening ILD, new SRC, inflammatory arthritis, new PAH, digital vasculopathy or impaired physical functioning
Original publication
Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study. Semin Arthritis Rheum. Published 31 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →